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Abstract
Objective: To determine if there is an increased maternal 
or neonatal morbidity in overweight and obese patients 
with a false positive glucose challenge test (GCT).
Methods: Patients with a body mass index (BMI)  ≥ 25.0 at 
registration were included in this prospective 36-month 
study. The study cohort consisted of patients with a false 
positive (FP) GCT, with two comparison cohorts: those with 
a (1) screen negative (SN) GCT result and (2) true positive (TP) 
GCT result. Risks were reported as odd ratios with 95% con-
fidence intervals, with a P < 0.05 considered as significant.
Results: There were 60 patients in the FP cohort, 106 in 
the SN cohort, and 64 in the TP cohort. When the BMI of 
the FP cohort was compared with either the SN cohort or 
TP cohort, differences were non-significant (SN 32.3 vs. 
FP 33.3 kg/m2, P = 0.067) and (FP 33.3 vs. TP 34.4 kg/m2, 
P = 0.303). When comparing the FP cohort to the SN cohort, 
patients in the FP group had significantly more gesta-
tional hypertension and pre-eclampsia. There was a trend 
towards delivering large for gestational weight infants and 
an infant  ≥ 4000 g in the FP cohort, but this fell short of 
reaching statistical significance. When comparing the 
FP to TP cohorts, rates of gestational hypertension, pre-
eclampsia, and infants  ≥ 4000 g were similar; however, 
neonatal morbidity was increased in the TP group.
Conclusions: Overweight and obese patients with a 
FP glucose challenge screen are more likely to have 
adverse maternal outcomes. Neonatal morbidity was not 
increased.
Keywords: false positive glucose challenge test; gesta-
tional diabetes; obesity.
Introduction
The risk of developing gestational diabetes mellitus (GDM) 
is increased 1.3–3.8 times in obese women compared to 
women of normal body mass index (BMI) [1]. GDM has been 
shown to increase the risk of both maternal and neonatal 
morbidity [2]. Because of this correlation, the diagnosis of 
GDM must be both accurate and precise. Thus, a two-step 
process has been implemented to confirm the presence of 
GDM: a screening test [glucose challenge test (GCT)] and a 
glucose tolerance test (GTT). Previous studies demonstrated 
conflicting data as to whether there is still an increased risk 
of adverse maternal and neonatal outcomes after a posi-
tive screening test, even if confirmatory testing for GDM is 
negative [3, 4]. In addition, many factors can affect glucose 
metabolism including advanced maternal age, BMI, or 
other medical co-morbidities [2]. Because the incidence of 
obesity is rising in the US, it is important to identify its role 
in both GDM testing and pregnancy outcomes. We sought to 
examine the potential effect of adverse maternal and neo-
natal outcomes associated with a false positive (FP) GCT in 
overweight and obese women.
Materials and methods
This study was conducted at Richmond University Medical Center, 
New York, a high-risk tertiary care center for obstetrics and neo-
nates. Patients that had prenatal care in our OB/GYN clinic during 
the time period from November 2012 to November 2015 were identi-
fied from our clinical database and data was prospectively collected. 
Patients who had a BMI ≥ 25.0, underwent an antenatal GCT, and 
subsequently delivered at our institution were included in the study. 
Patients with non-singleton gestations were excluded from analy-
sis. All patients received a 1  h 50 g GCT between 24 and 28 weeks’ 
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gestation. Serum glucose levels were measured 1 h after a 50 g glucose 
challenge was administered orally. If the GCT result was  < 140 mg/dL, 
then the test was considered a Screen Negative result (SN). If a GCT 
result  ≥ 140 mg/dL, a confirmatory 3 h 100 g GTT test was adminis-
tered. For the confirmatory GTT, a 100 g glucose load was adminis-
tered orally. Serum glucose levels were measured fasting, and at 1 h, 
2 h, and 3 h from the time of the 100 g glucose load administration. 
We utilized the Carpenter-Coustan criteria for diagnosing GDM, and 
the following cutoffs were used: fasting: 95 mg/dL, 1 h: 180 mg/dL, 
2 h: 155 mg/dL, and 3 h: 140 mg/dL. Serum glucose values above these 
cutoffs were considered abnormal. When two or more abnormal val-
ues were present, a diagnosis of gestational diabetes was established 
and the test was considered a true positive (TP). If less than two values 
were abnormal, the GCT result was considered to be a FP (Figure 1).
The study cohort consisted of patients with a FP result. Demo-
graphical data, antepartum, intrapartum, as well as neonatal out-
comes were compared amongst the FP, SN, and TP cohorts.
Maternal demographic data collected included age and BMI. 
Antepartum factors included were parity and primigravida status. 
The intra-partum factors assessed were gestational age at delivery, 
preterm delivery  < 34 weeks, preterm delivery 34–36.6 weeks, pres-
ence of gestational hypertension (defined as systolic blood pressure 
of 140 mm Hg or more or a diastolic pressure of 90 mm Hg or more 
on two occasions at least 4 h apart), preeclampsia (blood pressure 
according to definition of gestational hypertension with proteinuria: 
300 mg of protein or more in a 24-h urine collection or a protein (mg/
dL)/creatinine (mg/dL) ratio of 0.3 or higher), presence of maternal 
fever (temperature  ≥ 100.4°F), mode of delivery, and maternal cho-
rioamnionitis, The diagnosis of clinical chorioamnionitis was made 
if maternal fever was accompanied by at least two of the following 
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Figure 1: Schematic for assignment of patients to either the SN, FP, 
or TP cohort.
CC = Carpenter and Coustan values (fasting: 95 mg/dL, 1 h: 180 mg/dL, 
2 h: 155 mg/dL and 3 h: 140 mg/dL).
signs: fetal tachycardia  > 160 beats per minute, maternal leukocytosis 
(maternal white blood cell count  ≥ 15,000 cells/mm), uterine tender-
ness, or foul smelling vaginal discharge. Postpartum factors included 
were maternal wound infection, hospital length of stay, and readmis-
sion. Neonatal characteristics assessed included fetal weight, sex, 
and Apgar score. Neonatal morbidity assessments included hypo-
glycemia (glucose  < 40 mg/dL), hyperbilirubinemia (low risk: total 
serum bilirubin (TSB)  < 40th percentile for age in hours, low interme-
diate risk: TSB between 40th percentile – 75th percentile, high inter-
mediate risk: TSB between 75th percentile – 95th percentile, and high 
risk: TSB  > 95th percentile), large for gestational age infant (defined 
as an infant whose birthweight is  > 90th percentile for their given ges-
tational age), macrosomia defined as a birth weight  ≥ 4000 g regard-
less of gestational age, birth weight  ≥ 4500 g, incidence of shoulder 
dystocia, observed seizures within 48 h of life, incidence of neonatal 
intensive care (NICU) admission, requirement of neonatal mechani-
cal ventilation, fetal demise, and neonatal death. NICU admissions 
were left to the discretion of the admitting pediatrician.
An adverse maternal outcome was defined as any of the follow-
ing: preterm delivery, gestational hypertension, preeclampsia, cho-
rioamnionitis, maternal fever, cesarean delivery, wound infection, 
and readmission. Neonatal morbidity was defined by the occurrence 
of any of the following: neonatal hypoglycemia, hyperbilirubine-
mia, large for gestational age infant, birth weight  ≥ 4000 g, birth 
weight  ≥ 4500 g, shoulder dystocia, observed seizures within 48 h of 
life, NICU admission, requirement of neonatal mechanical ventila-
tion, fetal demise, and neonatal death.
For patients diagnosed with GDM, the following blood glucose 
targets were used for optimizing glucose control: fasting   ≤  90 mg/dL 
and 2-h postprandial   ≤  120 mg/dL. If patients did not respond to die-
tary modification, initiation of medication with either insulin ther-
apy or oral glyburide was determined on an individual basis.
Statistical analysis was carried out using IBM SPSS 22.0 (IBM 
Corporation, Armonk, NY, USA). Univariate analysis for continuous 
variables was compared using the Student’s t-test or the Mann-Whit-
ney U-test. Categorical data was compared using χ2-test or Fisher’s 
exact tests. A P-value of  < 0.05 was considered statistically signifi-
cant. Risks for statistically significant variables were reported as odd 
ratios with 95% confidence intervals. Power analysis for a χ2-test was 
conducted in G-POWER 3.1 (Faul and Erdfelder) to determine a suf-
ficient sample size using an α of 0.05, power of 0.80 and 2 degrees 
of freedom. A small-medium effect size (w = 0.21) was estimated for 
outcomes with prevalence greater that 6%, based on data by Stamilio 
et al. [3]. Based on the aforementioned assumptions, the desired total 
sample size necessary is 223 patients.
Results
Of the 230 patients that met the inclusion criteria, 106 
(46.1%) patients had a negative GCT result and were 
assigned to the SN cohort. Sixty patients (26.1%) had 
a positive GCT followed by a negative GTT, and were 
assigned to the FP cohort. Sixty-four patients (27.8%) had 
both a positive GCT and GTT, thus were included in the 
TP cohort. The maternal and neonatal demographic char-
acteristics of the three groups are summarized in Table 1. 
Significant differences were seen within the three cohorts 
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when the patient’s age at time of delivery was assessed. 
Patients in the FP group were older in age when compared 
to the SN group (SN 26.4 vs. FP 29.8 years, P  ≤  0.001), and 
patients in the FP group were significantly younger than 
the TP group (FP 29.8, TP 32.9 years, P = 0.001). There was a 
trend towards increasing BMI between cohorts, although 
it did not reach statistical significance. Patients in the FP 
cohort had a higher number of births compared to the 
SN group (SN 1.3 vs. FP 1.9, P = 0.043), but no significance 
was seen with the TP group (P = 0.372). When neonatal 
and maternal lengths of stay were compared amongst the 
groups, no differences were seen between the SN and FP 
group. However, the mean length of neonatal and mater-
nal hospital stay were both longer in the TP group when 
compared to those with a FP test result (neonatal length 
of stay FP 3.8 vs. TP 7.6 days, P = 0.001, maternal length of 
stay FP 3.7 vs. TP 4.2 days, P = 0.004). There were no dif-
ferences in gestational age at the time of delivery, fetal 
weight, and Apgar scores among the three cohorts.
Antepartum, intrapartum, postpartum, and neonatal 
outcome variables were also compared among the three 
groups. The data is summarized in Table 2. Significant dif-
ferences were seen between the SN and FP group. Patients 
in the FP cohort had significantly higher rates of gesta-
tional hypertension (OR 1.14, 95% CI 1.03–1.25, P  ≤  0.001) 
and pre-eclampsia (OR 3.11, 95% CI 1.98–9.97, P = 0.047) 
when compared to the SN group. When the FP cohort was 
compared to the TP cohort, rates of maternal hypertension, 
pre-eclampsia, and LGA infants and infants  ≥ 4000 g were 
similar. The TP cohort were more likely to have maternal 
fever (OR 2.45, 95% CI 1.06–5.65, P = 0.032), cesarean deliv-
ery (OR 2.53, 95% CI 1.21–5.28, P = 0.019), neonatal mechani-
cal ventilation (OR 4.47, 95% CI 1.39–14.38, P = 0.007), NICU 
admissions (OR 3.86, 95% CI 1.73–8.64, P < 0.001), and neo-
natal hypoglycemia (OR 5.12, 95% CI 1.78–14.74, P < 0.001), 
when compared to the FP group.
No differences were seen among the three groups 
when the following were compared: primigravida status, 
preterm deliveries, shoulder dystocia, male sex, neona-
tal seizures/tremors, neonatal hyperbilirubinemia, fetal 
demise, neonatal death, maternal re-admissions, and 
maternal wound infections.
Discussion
The identification of patients who are at increased risk for 
adverse maternal or fetal outcomes secondary to impaired 
glucose tolerance during pregnancy has been an area of 
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on the implications of a FP GCT result; however, the data 
is conflicting. Grotegut et  al. compared 165 women with 
FP GCT diagnosed by the Carpenter-Coustan criteria to a 
cohort of SN patients, and found no differences in mater-
nal or neonatal outcomes [4]. In contrast, in a cohort 
comprising of 164 patients with a FP GCT, Stamilio et al. 
found a higher incidence of adverse perinatal outcomes 
compared to patients with a negative GCT result [3]. Inter-
estingly, when Stamilio et al. sub-analyzed data based on 
patient BMI, they found an inverse relationship between 
BMI and the adverse perinatal outcomes. As the patient’s 
BMI increased, adverse perinatal outcomes attributed to 
a FP GCT result diminished linearly, and became statisti-
cally non-significant above a BMI of 25 kg/m2. They pos-
tulated that maternal obesity could have masked the risk 
attributed to a FP GCT.
Although previous studies have attempted to eluci-
date the prognostic significance of a FP glucose screen-
ing test [3–6], none have exclusively focused on a group of 
overweight and obese women. The presence of maternal 
obesity can be a confounding factor in studies, as obese 
women are at an increased risk for adverse pregnancy 
outcomes, independent of a FP GCT result [4]. Adverse 
outcomes attributed to maternal obesity include preec-
lampsia, gestational hypertension, GDM, LGA infants, 
thromboembolism, as well as cardiovascular and meta-
bolic disorders later in life [7].
In this study, overweight and obese patients with a FP 
GCT result had increased risk of adverse pregnancy com-
plications compared to patients of similar BMI with a SN 
GCT result. Compared to the SN cohort, patients in the FP 
group were more likely to have gestational hypertension 
and pre-eclampsia. Interestingly, the incidence of gesta-
tional hypertensive disorders in the FP cohort resembled 
that of the TP cohort. Additionally the incidence of deliver-
ing a LGA infant or an infant  ≥ 4000 g was similar between 
those in the FP cohort and the gestational diabetics (TP 
cohort). A trend towards increased shoulder dystocia was 
noted in the FP cohort compared to those who were SN, 
however, due to the rarity of this complication, it did not 
reach statistical significance.
In spite of the increased maternal morbidity in the 
FP cohort, certain neonatal morbidities, including need 
for mechanical ventilation, neonatal hypoglycemia, and 
NICU admission remained higher among the gestational 
diabetics. Gestational diabetics were also at an increased 
risk for intrapartum fever and cesarean delivery. The pres-
ence of intrapartum fever, combined with neonatal hypo-
glycemia and mechanical ventilation requirements were 
significantly higher in the TP cohort, and could have con-
tributed to the increased rate of NICU admissions in this 
group. Thus, patients in the FP cohort represent an inter-
mediate risk group that may benefit from further testing 
and close monitoring, especially those with an increased 
BMI, as this could augment risks.
Similar to other published studies, we show that 
patients with impaired glucose tolerance have an 
increased risk for pregnancy complications [2, 5, 6]. The 
hyperglycemia and adverse pregnancy outcome (HAPO) 
study prospectively examined 25,505 women that under-
went a 75 g oral glucose tolerance test (OGTT) between 24 
and 32 weeks of gestation [2]. The study showed an asso-
ciation between increasing maternal glucose levels and 
the following study outcomes: birthweight above 90th per-
centile, cesarean delivery, elevated cord serum C-peptide 
level, preterm delivery, shoulder dystocia, neonatal inten-
sive care unit admission, hyperbilirubinemia, and pre-
eclampsia [2]. The levels of maternal glycemia at which 
adverse outcomes occurred were well below the diagnos-
tic threshold for GDM [2].
The presence of both maternal obesity and impaired 
glucose tolerance is of increasing concern. A link between 
pregnancy, adiposity, and insulin resistance was first 
apparent when it was observed that levels of the pro-
inflammatory cytokine, tumor necrosis factor alpha 
(TNF-α) were increased in the adipose tissue of obese 
individuals [8]. Elevated levels of TNF-α impair glucose 
metabolism whereas the antagonism of TNF-α increases 
insulin sensitivity [8]. In addition, weight-loss was found 
to be associated with a reduction of TNF-α and reversal 
of insulin resistance [9]. It has been suggested that the 
increase in TNF-α and other pro-inflammatory cytokines, 
such as IL-6, observed in diabetic conditions, might result 
from oxidative stress and inflammatory changes caused 
by hyperglycemia [10].
Placental inflammation has been observed in preg-
nancies complicated by obesity [11] and GDM [12]. In 
normal pregnancy, a highly regulated inflammatory 
response is necessary to control several processes of pla-
centation and subsequent placental function [13]. Mater-
nal obesity and GDM have been associated with changes 
in placental nutrient transporter expression and activity 
[7]. The changes in placental function may be secondary 
to altered inflammatory cytokine profiles in the maternal, 
placental and fetal compartments leading to the co-mor-
bidities observed in these pregnancies [7].
With regard to the fetal compartment, Atègbo 
et  al. demonstrated that macrosomic neonates of GDM 
mothers had lower levels of adiponectin and leptin 
when compared to aged matched controls [14]. Adi-
ponectin, a physiologically active polypeptide hormone 
derived from adipose tissue, exhibits insulin-sensitizing 
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and anti-inflammatory properties. Leptin functions as 
an appetite suppressant [7, 14]. The pro-inflammatory 
mediatory, TNF-α, as well as IL-6, may be responsible 
for inhibiting the inulin sensitizing effects of both adi-
ponectin and leptin [14]. As these hormones have roles 
in glucose and weight regulation and are synergistic with 
one another, these findings show why neonates born to 
GDM mothers are more prone to fetal macrosomia and 
other associated adverse outcomes.
These findings are especially pertinent to our study. 
Patients with a TP GCT are diagnosed with GDM, and are 
therefore receiving the appropriate treatment and are 
monitored more closely. However, those with a FP GCT 
may also be at similar risk for several of these adverse out-
comes, but they are not being monitored. It is clear from 
this study, as well as other studies, that women with a 
FP GCT result are at increased risk for adverse outcomes. 
Maternal obesity adds an additional risk factor. There-
fore, large prospective studies that evaluate the effects of 
surveillance protocols on pregnancy outcomes in obese 
women with a FP GCT results are needed.
This is the first study to evaluate maternal and neo-
natal outcomes associated with a FP GCT result in women 
with increased BMI. We note some limitations in our study. 
First, this study is underpowered to assess outcomes that 
have a prevalence of  < 6%. Therefore definitive conclu-
sions cannot be inferred based on the non-significance of 
these variables.
Second, when the GCT was positive, we administered 
a confirmatory 100 g fasting GTT. Although this is stand-
ard in the US, diagnostic protocols differ in other parts of 
the world. This limits direct comparison to other studies 
that utilize the 2  h 75  mg OGTT. Differences in mean 
patient age among cohorts may have also influenced out-
comes. Finally, the patients that had a TP test result were 
diagnosed with gestational diabetes. Therefore, it is pos-
sible that their outcomes could have been altered due to 
the increased surveillance and intervention by providers. 
Management and treatment of patients diagnosed with 
gestational diabetes was left to the discretion of the treat-
ing obstetrician. We did not stratify patients in the TP 
cohort based on what therapy they received, or whether 
diet modification alone or medications were used to opti-
mize glucose control.
Conclusion
This study reveals the potential risks of overweight and 
obese women with FP GCT results may encounter during 
the course of their pregnancies. Patients with FP GCT 
results are more likely to experience adverse maternal 
outcomes than those with a SN GCT. Large prospective 
studies are needed to determine if the current guidelines 
and cutoff values used for the GCT and GTT require mod-
ification for overweight and obese patients. If patients 
with increased risks for maternal and fetal adverse 
events can be identified, appropriate surveillance and 
monitoring can be established in an attempt to optimize 
outcomes.
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